Clearside Biomedical (CLSD) Cut to “Strong Sell” at ValuEngine
ValuEngine downgraded shares of Clearside Biomedical (NASDAQ:CLSD) from a sell rating to a strong sell rating in a research report report published on Monday morning.
Other equities analysts have also recently issued research reports about the company. Cowen reissued a buy rating on shares of Clearside Biomedical in a report on Wednesday, October 25th. Zacks Investment Research raised Clearside Biomedical from a sell rating to a hold rating in a report on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Clearside Biomedical currently has an average rating of Hold and a consensus price target of $18.33.
Clearside Biomedical (CLSD) opened at $5.62 on Monday. Clearside Biomedical has a fifty-two week low of $5.44 and a fifty-two week high of $10.36. The company has a current ratio of 4.57, a quick ratio of 4.57 and a debt-to-equity ratio of 0.15.
In related news, Director Clay Thorp sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $7.02, for a total value of $105,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 70,000 shares of company stock valued at $476,500. Insiders own 20.90% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Nationwide Fund Advisors increased its holdings in shares of Clearside Biomedical by 118.3% in the second quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock valued at $107,000 after purchasing an additional 6,343 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Clearside Biomedical in the second quarter valued at approximately $117,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Clearside Biomedical in the second quarter valued at approximately $122,000. ProShare Advisors LLC increased its holdings in shares of Clearside Biomedical by 4.0% in the second quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock valued at $135,000 after purchasing an additional 563 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Clearside Biomedical by 21,620.7% in the second quarter. The Manufacturers Life Insurance Company now owns 17,811 shares of the company’s stock valued at $162,000 after purchasing an additional 17,729 shares during the last quarter. 51.66% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/02/09/clearside-biomedical-clsd-cut-to-strong-sell-at-valuengine.html.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.